For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1210/Next-Generation-Antibody-Therapies-World-Industry-and-Market-2014-2024
Pharma leader series top stem cell technology companies 2015 2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976)
or refer to our website: http://goo.gl/bhNICQ
Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027Visiongain
ย
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
Global Psoriasis Pipeline Drugs Market Assessment โ Forecast to 2023AzothAnalytics
ย
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
For an Executive Summary of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0124-ss
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
ย
The โGlobal mRNA Vaccines and Therapeutics Marketโ is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Migraine Pipeline Drugs Market Assessmentโ Forecast to 2022AzothAnalytics
ย
The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.
Top 25 Ophtalmic Drug Manufacturers 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024
Pharma leader series top stem cell technology companies 2015 2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976)
or refer to our website: http://goo.gl/bhNICQ
Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027Visiongain
ย
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
Global Psoriasis Pipeline Drugs Market Assessment โ Forecast to 2023AzothAnalytics
ย
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
For an Executive Summary of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0124-ss
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
ย
The โGlobal mRNA Vaccines and Therapeutics Marketโ is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Migraine Pipeline Drugs Market Assessmentโ Forecast to 2022AzothAnalytics
ย
The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.
Top 25 Ophtalmic Drug Manufacturers 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024
For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1149/Pre-Filled-Syringes-World-Industry-and-Market-Prospects-2014-2024
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
Scaffold Technology Market Size & Forecast, By Product (Hydrogels, Micro-Patterned Surface Microplates, Polymeric & Nanofiber Scaffold), By Application, By End-Use And Trend Analysis From 2018 To 2024
Global Animal Antibiotics and Antimicrobials Market (2017-2022) AzothAnalytics
ย
The global Animal Antibiotics & Antimicrobials industry has been driven by the rising demand for animal derived food products and increasing healthcare expenditure on pets due to rising pet ownership. Globally, the growth in Animal Antibiotics & Antimicrobials market is driven by growing middle class population.
http://azothanalytics.com/report/healthcare-pharma/global-animal-antibiotics-and-antimicrobials-market-analysis-product-type-delivery-type-type-of-animals-company-analysis-regional-and-country-analysis-2017-2022-r14142
Global Medical Sterilization Equipment Market (2017 Edition): Forecast to 2022AzothAnalytics
ย
Among the modes of sterilization, low temperature sterilization equipment is projected to witness fastest growth. Advent of technologically complex and intricate medical devices is anticipated to boost the global market of low temperature sterilization solutions in the forecast period. Among the regions, North America followed by Asia Pacific is predicted to advance at the highest rate, mainly driven by large population base, rapid economic development as well as swiftly rising number of surgical procedures. While there are associated guidelines on sternly maintaining proper sterilization standards in developed regions, there is an increasing awareness pertaining to maintaining hygienic standards within healthcare facilities in developing regions, thereby, contributing towards the market growth in regions such as Asia Pacific and Middle East. Contract sterilization services have been gaining major traction as the next major development in the industry; however, there are certain challenges that will need to be addressed. Stringent regulations regarding product approval causes delay in the manufacturing of new sterilization device and is responsible for hampering the growth of the medical sterilization equipment market.
Medical Device Leader Series: Needle Free Injection Device Developers, Manufa...Visiongain
ย
For an Executive Summary of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0122-ss
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1272/Ophthalmic-Devices-Market-Forecast-2014-2024
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Markntel Saudi Arabia Tumor Marker Market Analysis, 2020ShivaKumar1833
ย
โข The major growth factors for cancer biomarkers were increasing usage of biomarkers in cancer treatment in addition to R&D funding for pharma and biotech companies
โข The distribution channel was smoothly steering growth as Saudi Arabia imports from Europe and conducted tests.
Producing Biologics with C1. The cell expression system of the futureDyadic
ย
The C1 expression system has the potential to change the way in which both animal health and human biotech and pharmaceutical companies bring their biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with newer beneficial properties, and most importantly save lives.
Medical Device Regulations Global Overview And Guiding PrinciplesJacobe2008
ย
WHO Library Cataloguing-in-Publication Data
World Health Organization.
Medical device regulations : global overview and guiding principles.
1.Equipment and supplies โ legislation 2.Equipment and supplies โ
standards 3.Policy making 4.Risk management 5.Quality control I.Title.
ISBN 92 4 154618 2 (NLM Classification: WA 26)
Medical device industry 2014 - A Healthcare Sector AnalysisVikas Soni
ย
Medical Device Industry and its impact on Healthcare Sector of India for FY2014 along with Current Scenario of Global, US, EU and Indian Medical device market.
Information about variability is expressed in C through the usage of preprocessor directives which interact in multiple ways with proper C code, leading to systems dif๏ฌcult to understand and analyze. Lifting the variability information into a DSL to explicitly capture the features, relations among them and to the code, would substantially improve todayโs state of practice. In this paper we present a study which we performed on 5 large projects (including the Linux kernel) and almost 30M lines of code on extracting variability information from C ๏ฌles. Our main result is that by using simple heuristics, it is possible to interpret a large portion of the variability information present in large systems. Furthermore, we show how we extracted variability information from ChibiOS, a realtime OS available on 14 different core architectures, and how we lifted that information in mbeddr, a DSL-based technology stack for embedded programing with explicit support for
variability.
For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1149/Pre-Filled-Syringes-World-Industry-and-Market-Prospects-2014-2024
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
Scaffold Technology Market Size & Forecast, By Product (Hydrogels, Micro-Patterned Surface Microplates, Polymeric & Nanofiber Scaffold), By Application, By End-Use And Trend Analysis From 2018 To 2024
Global Animal Antibiotics and Antimicrobials Market (2017-2022) AzothAnalytics
ย
The global Animal Antibiotics & Antimicrobials industry has been driven by the rising demand for animal derived food products and increasing healthcare expenditure on pets due to rising pet ownership. Globally, the growth in Animal Antibiotics & Antimicrobials market is driven by growing middle class population.
http://azothanalytics.com/report/healthcare-pharma/global-animal-antibiotics-and-antimicrobials-market-analysis-product-type-delivery-type-type-of-animals-company-analysis-regional-and-country-analysis-2017-2022-r14142
Global Medical Sterilization Equipment Market (2017 Edition): Forecast to 2022AzothAnalytics
ย
Among the modes of sterilization, low temperature sterilization equipment is projected to witness fastest growth. Advent of technologically complex and intricate medical devices is anticipated to boost the global market of low temperature sterilization solutions in the forecast period. Among the regions, North America followed by Asia Pacific is predicted to advance at the highest rate, mainly driven by large population base, rapid economic development as well as swiftly rising number of surgical procedures. While there are associated guidelines on sternly maintaining proper sterilization standards in developed regions, there is an increasing awareness pertaining to maintaining hygienic standards within healthcare facilities in developing regions, thereby, contributing towards the market growth in regions such as Asia Pacific and Middle East. Contract sterilization services have been gaining major traction as the next major development in the industry; however, there are certain challenges that will need to be addressed. Stringent regulations regarding product approval causes delay in the manufacturing of new sterilization device and is responsible for hampering the growth of the medical sterilization equipment market.
Medical Device Leader Series: Needle Free Injection Device Developers, Manufa...Visiongain
ย
For an Executive Summary of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0122-ss
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1272/Ophthalmic-Devices-Market-Forecast-2014-2024
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Markntel Saudi Arabia Tumor Marker Market Analysis, 2020ShivaKumar1833
ย
โข The major growth factors for cancer biomarkers were increasing usage of biomarkers in cancer treatment in addition to R&D funding for pharma and biotech companies
โข The distribution channel was smoothly steering growth as Saudi Arabia imports from Europe and conducted tests.
Producing Biologics with C1. The cell expression system of the futureDyadic
ย
The C1 expression system has the potential to change the way in which both animal health and human biotech and pharmaceutical companies bring their biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with newer beneficial properties, and most importantly save lives.
Medical Device Regulations Global Overview And Guiding PrinciplesJacobe2008
ย
WHO Library Cataloguing-in-Publication Data
World Health Organization.
Medical device regulations : global overview and guiding principles.
1.Equipment and supplies โ legislation 2.Equipment and supplies โ
standards 3.Policy making 4.Risk management 5.Quality control I.Title.
ISBN 92 4 154618 2 (NLM Classification: WA 26)
Medical device industry 2014 - A Healthcare Sector AnalysisVikas Soni
ย
Medical Device Industry and its impact on Healthcare Sector of India for FY2014 along with Current Scenario of Global, US, EU and Indian Medical device market.
Information about variability is expressed in C through the usage of preprocessor directives which interact in multiple ways with proper C code, leading to systems dif๏ฌcult to understand and analyze. Lifting the variability information into a DSL to explicitly capture the features, relations among them and to the code, would substantially improve todayโs state of practice. In this paper we present a study which we performed on 5 large projects (including the Linux kernel) and almost 30M lines of code on extracting variability information from C ๏ฌles. Our main result is that by using simple heuristics, it is possible to interpret a large portion of the variability information present in large systems. Furthermore, we show how we extracted variability information from ChibiOS, a realtime OS available on 14 different core architectures, and how we lifted that information in mbeddr, a DSL-based technology stack for embedded programing with explicit support for
variability.
Women on Boards, Europeโs progress, Spain Grupo Dรญa Societรฉ Gรฉnรฉrale caseana maria llopis
ย
Women on Boards, Europeโs progress,
Spain Grupo Dรญa
Societรฉ Gรฉnรฉrale case
The crisis makes more relevant the need for parity and equality precisely due to women talent and abilities, more democratic, unifying, mediator, very experienced in balancing many responsibilities , taking faster decisions and agreements in a multidisciplinary win-win environment overcoming organizational, political and hierarchical barriers
Viven Reding, challenged European largest companies to adhere voluntarily to women equality in Management and Boards with quantitative objectives and dates, as of September only some 10 companies had signed
Women are โGood Businessโ in Business
There are studies that suggest a correlation between women participation in Boards and top management admin and better results for this companies vs. those that have less women. Mc Kinsey More profit, better risk management, better women talent recruitment and promotion programs
France, whose quota law passed in 2010, had the highest rate of increase in the percentage of women directors among their Fortune Global 200 companies -- from 7.2% in 2004 to 20.1% in 2011.
ย
The second highest rate of increase for women directors belongs to Spain, whose quota for women directors passed in 2007. Its Fortune Global 200 companies improved womenโs board representation from 1.9% in 2004 to 9.2% in 2011.
Advanced Wound Care World Market 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1198/Advanced-Wound-Care-World-Market-Forecast-2014-2024
Global cancer antibody drug conjugates market and pipeline insight 2022KuicK Research
ย
โGlobal Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022โ report highlights:
Impetus of Antibody Drug Conjugates
Mechanism of Cancer Antibody Drug Conjugates
Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
Marketed Cancer Antibody Drug Conjugate Clinical Insight
Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation and Phase
Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.
Antithrombotic Drugs World Industry 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1208/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2014-2024
Cell Line Development Market Size, Share & Trends Analysis Report by Product, By Source (Mammalian, Non-Mammalian), By Type of Cells, By Application, By Technology, And Segment Forecasts, 2012 - 2022
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongainglobal.com (+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1407/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2015-2025
Pharma leader series top 25 ophthalmic drug manufacturers 2015 2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website:
https://www.visiongain.com/Report/1407/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2015-2025
Cell Therapy Manufacturing Market - Industry Size, Share, Trend and Forecast ...TechSci Research
ย
According to #TechSci Research report, Cell Therapy Manufacturing Market stood at USD3123.44 million in 2020 and is expected to grow at a steady CAGR of 12.0% by 2026.
Gain More Insight: https://bit.ly/3nNpvH4
Get Sample Report: https://bit.ly/3cMuyRH
Press Release: https://bit.ly/3Jzx24w
Website: https://www.techsciresearch.com/
Market Research News: https://techsciblog.com/
Global antibody drug conjugate market & pipeline insight2020KuicK Research
ย
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Download Global antibody drug conjugate market & pipeline insight2020KuicK Research
ย
\" Global Antibody Drug Conjugate Market & Pipeline Insight 2020\" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Live Cell Imaging Market PPT: Overview, Dynamics, Trends, Segmentation, Appli...IMARC Group
ย
The global live cell imaging market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032.
More Info:- https://www.imarcgroup.com/live-cell-imaging-market
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
ย
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
ย
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
ย
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. Youโll also learn
โข Four (4) workplace discipline methods you should consider
โข The best and most practical approach to implementing workplace discipline.
โข Three (3) key tips to maintain a disciplined workplace.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
ย
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
Putting the SPARK into Virtual Training.pptxCynthia Clay
ย
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
ย
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
ย
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
"๐ฉ๐ฌ๐ฎ๐ผ๐ต ๐พ๐ฐ๐ป๐ฏ ๐ป๐ฑ ๐ฐ๐บ ๐ฏ๐จ๐ณ๐ญ ๐ซ๐ถ๐ต๐ฌ"
๐๐ ๐๐จ๐ฆ๐ฌ (๐๐ ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐๐๐ญ๐ข๐จ๐ง๐ฌ) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
๐๐ ๐๐จ๐ฆ๐ฌ provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
โญ ๐ ๐๐๐ญ๐ฎ๐ซ๐๐ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐ฌ:
โข 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
โข SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
โขFreenBecky 1st Fan Meeting in Vietnam
โขCHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
โข WOW K-Music Festival 2023
โข Winner [CROSS] Tour in HCM
โข Super Show 9 in HCM with Super Junior
โข HCMC - Gyeongsangbuk-do Culture and Tourism Festival
โข Korean Vietnam Partnership - Fair with LG
โข Korean President visits Samsung Electronics R&D Center
โข Vietnam Food Expo with Lotte Wellfood
"๐๐ฏ๐๐ซ๐ฒ ๐๐ฏ๐๐ง๐ญ ๐ข๐ฌ ๐ ๐ฌ๐ญ๐จ๐ซ๐ฒ, ๐ ๐ฌ๐ฉ๐๐๐ข๐๐ฅ ๐ฃ๐จ๐ฎ๐ซ๐ง๐๐ฒ. ๐๐ ๐๐ฅ๐ฐ๐๐ฒ๐ฌ ๐๐๐ฅ๐ข๐๐ฏ๐ ๐ญ๐ก๐๐ญ ๐ฌ๐ก๐จ๐ซ๐ญ๐ฅ๐ฒ ๐ฒ๐จ๐ฎ ๐ฐ๐ข๐ฅ๐ฅ ๐๐ ๐ ๐ฉ๐๐ซ๐ญ ๐จ๐ ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐จ๐ซ๐ข๐๐ฌ."
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
ย
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Next Generation Antibody Therapies World Industry 2014-2024
1. Next-Generation Antibody Therapies:
World Industry and Market
2014-2024
ยฉnotice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
2. Contents
1. Executive Summary
1.1 Next-Generation Therapies: World Market Review 2014
1.2 Report Contents
1.2.1 Benefits of this Report
1.3 Study Methods
1.3.1 Financial Information in this Report
1.3.2 Who is this Report for?
1.4 Introduction to Next-Generation Antibodies
1.4.1 Defining Next-Generation Antibodies
1.4.2 A Brief History of Antibody Drug Development
1.4.3 The Need for Next-Generation Technologies
1.4.4 Development Trends for Next-Generation Antibodies
2. The World Next-Generation Antibody Therapies Market: Outlook
and Forecast 2014-2024
2.1 The Next-Generation Antibody Therapies Market 2012-2023
2.1.1 Leading Sectors of the Next-Generation Antibody Therapies Market 2012-2013
2.1.1.1 There Are Products Approved in All Market Sectors
2.1.2 Next-Generation Antibodies in the Overall Antibody Market
2.2 The Next-Generation Antibody Therapies Market 2014-2024
2.2.1 Growth in the Antibody Therapies Market 2014-2024
2.2.2 Next-Generation Antibody Therapies: Market Forecast 2014-2024
2.2.3 Approvals in All Market Sectors Will Drive Growth to 2024
2.2.4 High Levels of Competition Will Restrain Growth in this Decade
2.2.5 ADCs Lead the Market in 2014
2.2.5.1 ADCs Will Account for 40% in 2018
2.2.5.2 What Will Be the Leading Market Sector in 2024?
www.visiongain.com
3. Contents
2.3 Leading National Markets for Next-Generation Antibody Therapies 2014-2024
2.3.1 The US Leads the Market in 2014
2.3.1.1 US Submarket Forecast 2014-2024
2.3.2 Next Generation Antibodies in the EU 2014-2024
2.3.3 The Japanese Submarket 2014-2024
2.3.4 Demand for Next-Generation Antibody Therapies in Emerging National Markets
3. Antibody-Drug Conjugates (ADCs): Pipeline and Commercial
Outlook 2014-2024
3.1 ADC Submarket 2012-2013
3.1.1 Two Products Launched Since 2011
3.1.2 Mylotarg: The First ADC Is No Longer Marketed
3.2 ADC Submarket 2014-2024
3.2.1 ADC Submarket Forecast 2014-2024
3.2.2 ADC Submarket Drivers: A Long and Growing R&D Pipeline
3.2.3 Competition for Leading Drugs Will Restrain Growth 2014-2024
3.2.3.1 Manufacturing ADCs Forms a Challenge
3.3 Adcetris (Brentuximab Vedotin, Seattle Genetics/Takeda)
3.3.1 Expanding the Label for Future Revenue Growth
3.3.2 Adcetris: Revenue Forecast 2014-2024
3.4 Kadcyla (Trastuzumab Emtansine, Roche)
3.4.1 Part of Rocheโs HER2 Portfolio
3.4.2 Kadcyla: Revenue Forecast 2014-2024
3.5 Two Platforms Dominate the Pipeline in 2014
3.5.1 Seattle Geneticsโ Platform Accounts for 60% of the Clinical Pipeline
3.5.2 ImmunoGen: TAP Technology
3.5.3 Leading Biotechs Are Assessing Both Platforms
3.5.4 Other Platforms for ADC Development
3.5.4.1 Immunomedics: Lower Potency Cytotoxics for Extended Use
www.visiongain.com
4. Contents
3.5.4.2 Synthon Biopharmaceuticals
3.5.5 ADCs Are Attracting High Value Deals
3.6 ADC Pipeline: Outlook 2014-2024
3.6.1 The Longest Pipeline in the Next-Generation Antibodies Market
3.6.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
3.6.3 Pfizerโs CMC544 Is the Only Phase III Candidate
3.6.4 Roche Has Eight Clinical-Stage Candidates
3.6.4.1 RG7593 and RG7596: ADCs for NHL
3.6.4.2 Three Candidates for Ovarian Cancer
3.6.4.3 RG7450 for Prostate Cancer
3.6.5 CDX-011: Another ADC for Breast Cancer Patient Subsets
3.6.6 SAR3419 (Sanofi): Targeting CD19 in Lymphoma
3.6.7 BT-062 (Biotest)
3.6.8 Immunomedics: Two Phase II ADCs from its Proprietary Platform
3.6.9 PSMA ADC (Progenics Pharmaceuticals): A Second Candidate for Prostate Cancer
3.6.10 ABT-414 (AbbVie)
3.6.11 Seattle Genetics: Three Phase I Candidates
3.6.11.1 SGN-CD33A: Using a New Cytotoxin and Linker Technology
3.6.12 Astellas Pharma: Partnered with Seattle Genetics for Phase I ADCs
3.6.13 ImmunoGen: Three Phase I Candidates
3.6.14 SAR566658 (Sanofi)
3.6.15 MLN0264 (Millennium Pharmaceuticals)
3.6.16 AMG 595 (Amgen)
3.6.17 BAY 94-9343 (Bayer)
3.6.18 AMG 172 (Amgen)
3.6.19 PF-06263507 (Pfizer)
3.6.20 HuMax-TF-ADC (Genmab)
3.7 Future Developments in ADC Technology
3.7.1 Site-Specific Linkage for Improved Safety Profiles
www.visiongain.com
5. Contents
4. The Engineered Antibodies Submarket 2014-2024
4.1 The Engineered Antibodies Submarket 2012-2013
4.1.1 Two Engineered Antibodies Approved 2012-2013
4.2 The Engineered Antibodies Submarket Forecast 2014-2024
4.2.1 What Will Drive Submarket Growth to 2024?
4.2.2 Engineered Antibodies: Submarket Restraints 2014-2024
4.3 Poteligeo: The First Engineered Antibody Is Only Available in Japan
4.3.1 Poteligeo: Revenue Forecast 2014-2024
4.4 Gazyva: A Follow-On to Rocheโs Marketing-Leading Rituxan
4.4.1 Gazyva as a Challenger in the anti-CD20 Market
4.4.1.1 Competition beyond Rituxan and Biosimilars
4.4.2 Gazyva: Revenue Forecast 2014-2024
4.5 Leading Technology Platforms for Engineered Antibodies 2014-2024
4.5.1 Enhancing ADCC: The Potelligent Platform
4.5.2 Roche Glycart: Glycosylation for Improved ADCC
4.5.3 XmAb (Xencor): Modifying Amino Acids in the Fc Domain
4.5.4 Other Platforms for Increased Potency
4.5.4.1 GlycoExpress (Glycotope)
4.6 Engineered Antibodies Pipeline 2014
4.6.1 Pipeline Changes 2011-2013
4.6.2 Benralizumab (MedImmune/Kyowa Hakko Kirin)
4.6.3 Margetuximab (MacroGenics)
4.6.4 MEDI-551: MedImmune and Kyowaโs Second Collaboration
4.6.5 MOR-208 (Xencor/MorphoSys)
4.6.6 PankoMab-GEX: Glycotopeโs Lead Candidate
4.6.7 Teplizumab: Failed in Phase III but Undergoing Phase II Investigator-Led Studies
4.6.8 Kyowa Hakko Kirin Has Four Early-Stage Candidates
4.6.9 Ocaratuzumab (Mentrik Biotech): Phase I for NHL
www.visiongain.com
6. Contents
4.6.10 Ublituximab (TG Therapeutics/LFB)
4.6.11 XmAb5871 (Xencor/Amgen)
4.6.12 RG7116: A Future Addition to Rocheโs Breast Cancer Portfolio
4.6.13 CetuGEX and TrasGEX: Two Early-Stage Glycotope Biosuperiors
4.6.14 MGA271 (MacroGenics/Servier)
5. The Bispecific Antibodies Submarket: Commercial Potential 20142024
5.1 The Bispecific Antibodies Submarket 2012-2013
5.2 The Bispecific Antibodies Submarket 2014-2024
5.2.1 Commercial Outlook for Bispecific Antibodies: Revenue Forecast 2014-2024
5.2.2 Bispecific Antibodies: Submarket Drivers 2014-2024
5.2.3 Bispecific Antibodies: Submarket Restraints 2014-2024
5.2.3.1 Manufacturing Bispecific Antibodies: Maintaining Stability and Purification
5.3 Removab: The First Bispecific Antibody
5.3.1 Removab: Revenue Forecast 2014-2024
5.4 Many Platforms Are Under Investigation to Develop Bispecific Antibodies
5.4.1 BiTE Platform: The Current Market Leader
5.4.2 MacroGenicsโ DART Platform Holds Promise
5.4.3 TriomAbs (TRION Pharma): Limited Market Impact 2014-2024
5.4.4 ImmTAC (Immunocore)
5.4.5 DuoBodies (Genmab)
5.5 A Growing Pipeline for Bispecific Antibodies
5.5.1 Blinatumomab (Amgen): The Only Phase III Bispecific Antibody
5.5.1.1 The Outlook for Blinatumomab in ALL
5.5.2 Symphogen Has Two Phase II Candidates
5.5.2.1 Symphogenโs Recombinant Antibody Mixtures
5.5.3 MM-111 (Merrimack Pharmaceuticals)
5.5.4 IMCgp100 (Immunocore)
www.visiongain.com
7. Contents
5.5.5 BAY2010112 (Bayer)
5.5.6 MEDI-565: A Third BiTE Candidate
5.5.7 AFM13 (Affimed Therapeutics)
5.5.8 TF2: Utilising Immunomedicsโ Dock-and-Lock Platform
5.5.9 MM-141 (Merrimack Pharmaceuticals)
5.5.10 SAR156597 (Sanofi)
6. The Next-Generation Antibody Fragments and Antibody-Like
Proteins (ALPs) Submarket 2014-2024
6.1 There Is One Marketed Product in 2014
6.1.1 Kalbitor (Ecallantide, Dyax)
6.1.1.1 Kalbitor: Revenue Forecast 2014-2024
6.2 Outlook for the Antibody Fragments and ALPs Submarket 2014-2024
6.2.1 Antibody Fragments and ALPs Submarket Forecast 2014-2024
6.2.2 Investment from Big Pharma Will Drive Growth 2014-2024
6.2.3 No Late-Stage Candidates to Restrain Growth to 2024
6.3 There Are Many Development Platforms in this Sector
6.3.1 Single-chain Variable Fragment Platforms
6.3.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
6.3.2 Nanobodies: The Smallest Antibody Fragment
6.3.2.1 Ablynxโ Nanobody Platform Has Created Many Clinical Candidates
6.3.3 Domain Antibodies: GSK and Crescendo Biologics
6.3.4 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
6.3.4.1 DARPins: One Tenth the Size of Antibodies
6.3.4.2 Anticalins (Pieris): Tested in Clinical Trials
6.3.4.3 Affibodies
6.3.4.4 Fynomers (Covagen)
6.3.4.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development
6.3.4.6 Adnectins (Bristol-Myers Squibb)
www.visiongain.com
8. Contents
6.3.5 Which Platform Will Lead the Market 2014-2024?
6.4 Clinical Development of Next-Generation Antibody Fragments and ALPs
6.4.1 Limited Activity for Five Clinical Candidates 2013-2014
6.4.2 Ablynx Leads the Pipeline with Seven Clinical Projects
6.4.2.1 ALX-0061: AbbVie Partners for RA Development
6.4.2.2 ALX-0141: A Next-Generation Osteoporosis Therapy
6.4.2.3 ALX-0761: A Third RA Candidate
6.4.3 AGN-150998: Development Delayed for Allerganโs AMD Product
6.4.4 ESBA1008: An Ophthalmology Competitor in Phase II
6.4.5 DLX105 (Delenex Therapeutics)
6.4.6 GSK Has Two Early-Stage Candidates: GSK1995057 and GSK2374697
6.4.7 PRS-050 (Pieris): Targeting VEGF in Solid Tumours
7. The Biosimilar Antibodies Submarket 2014-2024
7.1 Biosimilar Antibodies Are the Target for Many Follow-On Biologics Developers
7.2 More Than Five Biosimilars Approved Worldwide in 2014
7.2.1 Biosimilar Antibodies Submarket 2013: Revenues from Emerging Markets Only
7.3 The Biosimilar Antibodies Submarket 2014-2024
7.3.1 Rapid Growth in Revenues Forecast from 2015 Onwards
7.3.2 Launches in the US and EU to Drive Growth to 2024
7.3.3 How Can Developers Ensure Uptake Among Physicians?
7.3.3.1 Automatic Substitution of Biosimilar Antibodies
7.3.4 Patent Expiries Will Hit Many Leading Antibodies in this Decade
7.3.5 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
7.4 Biosimilar Rituximab 2014-2024
7.4.1 Reditux: The First Rituximab Biosimilar in the World
7.4.1.1 Mabtas: Biosimilar Competition in India
7.4.2 Kikuzubam: Biosimilar Competition for Roche in Latin America
7.4.3 Biosimilar Rituximab Pipeline 2014
www.visiongain.com
9. Contents
7.4.3.1 Two Companies Halted Development 2012-2013
7.4.3.2 Celltrion: Development Delayed 2013
7.4.3.3 GP2013: Sandoz Is the Pipeline Leader
7.4.3.4 BI 695500 (Boehringer Ingelheim)
7.4.3.5 MabionCD20: Mabion Prepares Phase III for Developed Markets
7.4.3.6 BCD-020 (Biocad)
7.4.3.7 PF-05280586 (Pfizer)
7.4.4 Biosimilar Rituximab: Revenue Forecast 2014-2024
7.5 Biosimilar Infliximab: The First Target for Developed Markets
7.5.1 Inflectra/Remsima: Approved in South Korea and the EU
7.5.1.1 Flammegis: Egis Pharmaceuticals Markets the Biosimilar in Eastern Europe
7.5.2 Biosimilar Infliximab Pipeline 2014
7.5.2.1 BOW-015: Epirus Targets Emerging Markets First
7.5.2.2 Reliance Life Sciences: Biosimilar Infliximab in India
7.5.3 Biosimilar Infliximab: Revenue Forecast 2014-2024
7.6 Biosimilar Trastuzumab 2014-2024
7.6.1 CANMAb: The First Biosimilar Trastuzumab Approved in India
7.6.2 Herzuma: Approved in South Korea 2014
7.6.3 Fewer Clinical Candidates than for Biosimilar Rituximab 2014
7.6.3.1 Amgen and Actavis Advance to Phase III
7.6.3.2 Pfizer: A Third Candidate Set for Phase III
7.6.4 Biosimilar Trastuzumab: Revenue Forecast 2014-2024
7.7 Biosimilar Adalimumab 2014-2024
7.7.1 Humira Is the Worldโs Leading Antibody Therapy
7.7.1.1 AbbVie Seeks to Protect its Lead Asset
7.7.2 Biosimilar Adalimumab Pipeline 2014
7.7.2.1 Amgen Advances to Phase III
7.7.2.2 Sandoz: A Second Phase III Candidate
7.7.2.3 Pfizer and Boehringer Ingelheim: Two Biosimilars in Phase I
7.7.3 Biosimilar Adalimumab: Revenue Forecast 2014-2024
www.visiongain.com
10. Contents
8. Next-Generation Antibodies: Industry Trends 2014-2024
8.1 Next-Generation Antibodies: Strengths and Weaknesses 2014
8.1.1 Approved Products Indicate a Path to Market Acceptance
8.1.2 Challenges Exist With Current Monoclonal Antibody Therapies
8.2 Next-Generation Antibodies: Opportunities and Threats 2014-2024
8.2.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
8.2.2 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
8.3 Next-Generation Antibodies: STEP Analysis 2014-2024
8.3.1 Social Factors: Rising Demand for Cancer Therapies
8.3.1.1 Cancer Incidence Is Rising Rapidly
8.3.1.2 Next-Generation Antibodies for Personalised Medicine
8.3.2 Technological Developments Will Drive Pipeline Growth
8.3.2.1 There Are Many Competing Platforms
8.3.2.2 Manufacturing Challenges Exist for Most Sectors
8.3.2.3 New Analytical Tools for Target Identification and Protein Characterisation
8.3.3 Economic Pressures
8.3.3.1 Next-Generation Antibodies Are High-Cost
8.3.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
8.3.3.3 Next-Generation Launches for Product Lifecycle Management
8.3.4 Political and Regulatory Issues
8.3.4.1 Regulatory Challenges for Biosimilar Antibodies
8.4 Key Targets for Next-Generation Antibody Development 2014-2024
8.4.1 Oncology Is the Lead Indication in All Sectors
8.4.1.1 HER2 and HER3 for Breast Cancer
8.4.1.2 CD19 and CD20 for Lymphoma and Leukaemia
www.visiongain.com
11. Contents
9. Research Interviews 2013-2014
9.1 Dr Edwin Moses, CEO, Ablynx
9.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
9.1.1.1 Manufacturing Nanobodies
9.1.2 Turning Challenges to Advantages
9.1.3 Nanobodies Are Further Developed than Other Antibody Scaffolds
9.1.4 The Commercial Potential for Nanobodies
9.1.5 Next-Generation Antibodies in China and Other Emerging Markets
9.2 Dr Marco Timmers, CSO, Synthon
9.2.1 Synthon
9.2.2.1 Second-Generation ADC Development
9.2.2 Key Benefits to Synthonโs ADC Technology
9.2.2.1 Broader Use in HER2-Positive Disease
9.2.3 Clinical Development of Synthonโs ADCs
9.2.4 Challenges in Developing ADCs
9.2.4.1 High Manufacturing Costs for Advanced Technologies
9.2.4.2 Regulatory Risks in ADC Development
9.2.5 Data Reporting for ADC Development
9.3 Dr Ivan Horak, CSO and CMO, Symphogen
9.3.1 Advantages of Antibody Mixtures
9.3.2 Activating the Immune System
9.3.3 Symphogenโs Pipeline Outlook
9.3.4 The Next Ten Years
10. Conclusions to Our Study
10.1 The Next-Generation Antibody Therapies Market 2012-2013
10.1.1 ADCs Lead the Next-Generation Antibodies Market in 2014
www.visiongain.com
12. Contents
10.2 Outlook for the Next-Generation Antibody Therapies Market 2014-2024
10.2.1 Growth in the Market 2014-2024
10.2.2 Commercial Drivers for Growth to 2024
10.2.3 Threats and Opportunities Exist in the Market 2014-2024
www.visiongain.com
13. Contents
List of Tables
Table 1.1 Currency Exchange Rates, 2013
Table 1.2 Monoclonal Antibody Types and Sources, 2014
Table 2.1 Next-Generation Antibody Therapies Market: Revenues ($m), 2008-2013
Table 2.2 Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%)
by Sector, 2012
Table 2.3 Next-Generation Antibody Therapies Approved, 2014
Table 2.4 Antibody Therapies Market: Revenues ($m) and Market Shares (%), 2012
Table 2.5 Antibody Therapies Market Forecast ($m), 2012-2024
Table 2.6 Next-Generation Antibodies Market: Overall Market and Revenue Forecasts ($m) by
Sector, 2012-2024
Table 2.7 Next-Generation Antibody Therapies Market: Submarket Shares (%), 2012-2024
Table 2.8 Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%)
by Country/Region, 2012
Table 2.9 Next-Generation Antibodies Market: Overall Market and Revenue Forecasts ($m) by
Country/Region, 2012-2024
Table 2.10 US Next-Generation Antibody Therapies Submarket Forecast ($m), 2012-2024
Table 2.11 EU Next-Generation Antibody Therapies Submarket Forecast ($m), 2012-2024
Table 2.12 Next-Generation Antibody Therapies Market: Regional Submarket Shares (%), 20122024
Table 2.13 Japanese Next-Generation Antibody Therapies Submarket Forecast ($m), 2012-2024
Table 3.1 ADC Submarket: Revenues ($m) and Market Shares (%) by Drug, 2011-2013
Table 3.2 ADC Submarket: Overall Submarket and Revenue Forecasts ($m) by Drug, 2012-2024
Table 3.3 Adcetris: Revenue ($m) by Company, 2011-2013
www.visiongain.com
20. Contents
Companies and Other Organisations Mentioned
AbbVie
Abgenix (part of Amgen)
Ablynx
Actavis
ADC Therapeutics
Adnexus (part of Bristol-Myers Squibb)
AET BioTech
Affibody
Affimed Therapeutics
Agensys (part of Astellas Pharma)
Alcon (part of Novartis)
Alexion Pharmaceuticals
Allergan
Allozyne
Ambrx
Amgen
AMRI
Aprogen
Arana Therapeutics (part of Cephalon)
Astellas Pharma
AstraZeneca
Auven Therapeutics
Bayer Healthcare
Biocad
Bioceros
Biocon
Biogen Idec
www.visiongain.com
21. Contents
Biotest
BioWa (part of Kyowa Hakko Kirin)
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
BZL Biologics
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Celltech (part of UCB)
Celltrion
Cephalon (part of Teva)
CinnaGen
Comisiรณn Federal para la Protecciรณn contra Riesgos Sanitarios (Cofepris) [Mexico]
Concortis Biosystems (part of Sorrento Therapeutics)
Corixa
Covagen
Crescendo Biologics
CVie Therapeutics
CytomX Therapeutics
Daiichi Sankyo
Defiante Farmaceutica (part of Sigma-Tau)
Delenex Therapeutics
Dendreon
Domantis (part of GSK)
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Dyax
Eddingpharm
www.visiongain.com
22. Contents
Egis Pharmaceuticals
Elan Pharmaceuticals
Eli Lilly
Epirus Biopharmaceuticals
ESBATech (part of Novartis)
ETH Zurich
European Medicines Agency (EMA)
EvaluatePharma (now Evaluate)
F-star
Five Prime Therapeutics
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fresenius Group
Fujifilm
Fujifilm Diosynth Biotechnologies
Fujifilm Kyowa Kirin Biologics
GE Healthcare
Gedeon Richter
Genentech (part of Roche)
Genmab
Gilead Sciences
GlycoExpress
Glycotope
GSK
Hanwha Chemical
Helmholtz Zentrum Mรผnchen
Hospira
IBC Pharmaceuticals (part of Immunomedics)
Igenica
Immunocore
www.visiongain.com
23. Contents
ImmunoGen
Immunomedics
Intas Biopharmaceuticals
Isu Abxis
J&J
Janssen Biotech (part of J&J)
Janssen-Cilag (part of J&J)
KaloBios
Karolinska Institute
Kyowa Hakko Kirin
Kyowa Medex (part of Kyowa Hakko Kirin)
Laboratoires Franรงais de Fractionnement et des Biotechnologies (LFB)
LFB Biomanufacturing (part of LFB)
Life Science Pharmaceuticals
LINDIS Biotech
LMC
Lonza
Mabion
MacroGenics
MedImmune (part of AstraZeneca)
Mentrik Biotech
Merck & Co.
Merck Serono
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus Biopharmaceuticals
Micromet (part of Amgen)
Millennium Pharmaceuticals (part of Takeda)
Ministry of Food and Drug Safety (MFDS) [South Korea]
Ministry of Health [Brazil]
www.visiongain.com
24. Contents
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mylan
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nektar Therapeutics
Neopharm Group
Nichi-Iko Pharmaceutical
Novartis
Novellus Biopharma
Orygen Biotecnologia
Oxford BioMedica
Oxford BioTherapeutics
Pfizer
Pharmacyclics
PharmaPraxis
Pieris
Piramal Group
PlantForm
Probiomed
Progenics Pharmaceuticals
ProStrakan Group (part of Kyowa Hakko Kirin)
Ranbaxy Laboratories (part of Daiichi Sankyo)
Redwood Bioscience
Regeneron Pharmaceuticals
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Life Sciences
www.visiongain.com
25. Contents
Roche
Roche Glycart (part of Roche)
Royal Institute of Technology (KTH) [Sweden]
SAFC
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
Scil Proteins
Seattle Genetics
Servier
Shanghai CP Guojian
Sigma-Tau Pharmaceuticals
Sorrento Therapeutics
Sothema Laboratories
Spectrum Pharmaceuticals
Spirogen (part of AstraZeneca)
Stada
Stelis Biopharmaceuticals (part of Strides Arcolab)
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Symphogen
Synthon
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Talon Therapeutics (part of Spectrum Pharmaceuticals)
Targa Therapeutics
Teva Pharmaceutical Industries
www.visiongain.com
27. Next-Generation Antibody Therapies:
World Industry and Market 2014-2024
4.4.2 Gazyva: Revenue Forecast 2014-2024
Uptake of Gazyva in its first year on the market, in direct competition with Rituxan, will provide a
good indication of the revenue potential for the drug. If it gains rapid uptake, visiongain believes
that Roche will be able to switch patients from the older therapy before biosimilars enter the US
and EU markets - these will be priced well below the cost of Gazyva, which is expected to be close
to $80,000 annually in the US. We predict that by 2018, revenue for Gazyva will have reached
$919m, up from $200m in 2014. Approvals in additional indications in this period will drive growth,
as will the launch in the EU and Japan. Biosimilar competition and competition from other antiCD20 antibody therapies will restrain growth throughout the period. However, we predict that
Gazyva will achieve blockbuster revenue - by 2024, revenue for the drug will have reached
$1,773m (Table 4.4 and Figure 4.5).
Figure 4.5 Gazyva: Revenue Forecast ($m), 2012-2024
1,800
1,600
1,400
Revenue ($m)
1,200
1,000
800
600
400
200
0
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Year
Source: visiongain 2014
Table 4.4 Gazyva: Revenue Forecast ($m), 2012-2024
2012
Revenue ($m)
2013
2014
2015
2016
2017
2018
0
0
200
344
533
741
919
72
55
39
24
Annual Growth (%)
CAGR (%, 2014-2018)
46.4
2019
2020
2021
2022
2023
2024
Revenue ($m)
1,094
1,269
1,421
1,549
1,657
1,773
Annual Growth (%)
19
16
12
9
7
7
CAGR (%)
11.6
Source: visiongain 2014
www.visiongain.com
Page 98
28. Next-Generation Antibody Therapies:
World Industry and Market 2014-2024
4.5 Leading Technology Platforms for Engineered Antibodies 2014-2024
Two antibody engineering platforms have produced commercial products in 2014 - Kyowa Hakko
Kirinโs Potelligent and Roche Glycartโs GlycoMAbs. The Potelligent platform has also produced five
further clinical-stage drugs, accounting for almost a third of the pipeline in this sector (Table 4.5
and Figure 4.6). MacroGenics and Glycotope have produced three clinical trial drugs from their
engineered antibody platforms. By contrast, Roche only has one drug in clinical trials, following the
approval of Gazyva in 2013, as well as the discontinuation of one project in that year.
Thus far, antibody engineering platforms have focused on enhancing two of the characteristics
discussed at the beginning of this chapter - ADCC and half-life. Extending half-life is beneficial as it
provides a more convenient dosing regimen, as well as greater efficacy for the drug. The two
leading platforms achieve enhanced ADCC by defucolsylating the antibody - removing the fucose
sugar units from the Fc domain. Fucose on an antibodyโs Fc domain has been linked to lower
ADCC activity against tumour cells. Visiongain believes that only one company has tested an
amino acid-modifying platform in clinical trials so far - Xencor reports that modifying as few as two
amino acids in the Fc domain can have a significant impact on ADCC activity. Unlike the
glycoengineering platforms, Xencorโs platform can also be used to extend antibody half-lives, we
note.
Figure 4.6 Engineered Antibodies Pipeline by Technology Platform, 2014
Roche
6.3%
Other
12.5%
Kyowa Hakko Kirin
31.3%
Xencor
12.5%
Glycotope
18.8%
MacroGenics
18.8%
Source: visiongain 2014
www.visiongain.com
Page 99